LSX Nordic Congress, Copenhagen, Denmark, 6-7 September 2022.

The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region.

It connects life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalisation of Nordic life science and healthcare innovation.

The mission is to facilitate ever greater international investment into the region, as well as foster strategic partnerships and collaboration with international healthcare stakeholders.

(May 2022)

NLS Days, Malmö, Sweden, 28-29 September 2022.

Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science and created a unique place to do business. Most attendees express their delight in the informal atmosphere, combined with an organized approach to meeting highly relevant people.

(November 2021)

BioPharm America, Boston, USA, 28-29 September 2022.

BioPharm America attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts and it’s the perfect opportunity to engage with global life science partners. BioPharm America is where biotech industry partnerships get started. This year's conference will be open for both meetings in-person and virtually.

(April 2022)

BIO-Europe, Leipzig, Germany, 24-26 October 2022.

BIO-Europe is back in person! Your gateway to the global biopharma community.

BIO-Europe is scheduled to take place October 24–26 in Leipzig, Germany, and digitally on November 2-4. This will be the first in-person BIO-Europe since its 2019 edition in Hamburg, Germany. It’s time to build real bridges with real people again. Meet, engage and network with over 4,000 global biopharma executives and take part in the 25,000+ one-to-one meetings that will take place at the event.

(August 2022)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4^th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.

(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

(June 2018)